Navigation Links
Jefferson researchers find nanoparticle shows promise in reducing radiation side effects

A gene responsible for the production of a protein called vasostatin may prove a promising new way of treating pancreatic cancer, suggests research published ahead of print in Gut.

Pancreatic cancer is the fifth leading cause of cancer deaths in the developed world, and is extremely difficult to treat. Only 3% of affected patients are still alive five years after diagnosis, a survival rate that has remained static for the past three decades.

Currently, the only viable treatment is surgery. Radiotherapy and chemotherapy have little impact on the disease.

The research team investigated the potential of the protein vasostatin to suppress the development of new blood vessels and pancreatic tumour cells both in test tubes and in mice with pancreatic cancer.

'Solid' tumours, such as pancreatic cancer, are heavily dependent on a rich blood supply to enable them to grow rapidly and spread throughout the body. This process is known as angiogenesis.

The protein gene was incorporated into a virus (adenovirus), so that it would be able to penetrate the cells, acting as a vector.

The test tube experiments showed that 72 hours after infection with the genetically modified virus, vasostatin was clearly active in the tissue. Tumour growth in the mice was also curbed, and when compared with mice which had not been infected with the virus, the difference between the two groups was highly significant.

The researchers then looked more closely at the pancreatic cells and the cell linings of the blood vessels (vascular endothelial cells).

They found that although vasostatin seemed to have little impact on the pancreatic cells, it blocked the formation of new blood vessels, effectively cutting off the supply of nutrients to the malignant cells. This effect was seen in both the test tube and animal experiments.

This type of gene therapy "may be a potent strategy to treat many malignant tumours, including pancreatic can cer, and represents a promising therapeutic option for malignancy with a poor prognosis," conclude the authors.


'"/>

Source:Thomas Jefferson University


Related biology news :

1. Jefferson Virologists Coax HIV Out of Hiding
2. Jefferson biologist coaxing human embryonic stem cells to make dopamine with simpler, faster method
3. Jefferson scientists identify gene defect leading to abnormal skin development and cancer
4. Jefferson researchers building a better rabies vaccine
5. Jefferson scientists identify gene mutation potentially involved in breast cancer initiation
6. Immune cell communication key to hunting viruses, Jefferson immunologists show
7. Jefferson researchers uncover new way nature turns genes on and off
8. Jefferson scientists find aging gene also protects against prostate cancer development
9. Jefferson scientists find high glucose before surgery raises risk of dangerous complications
10. Jefferson researchers discovery may change thinking on how viruses invade the brain
11. Elderly spinal cord injuries increase five-fold in 30 years, Jefferson neurosurgeons find
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/11/2018)... ... 10, 2018 , ... For the first time, an app ... about their treatment options. The unique patient education tool seeks to improve survival ... was developed through a collaboration between the Centers for Disease Control and ...
(Date:10/5/2018)... Utah and BOSTON (PRWEB) , ... October 04, ... ... in delivering cloud-based enterprise-class unified communications and collaboration solutions, was present at Microsoft ... support of Office 365 communication solutions. , Microsoft issued a statement about the ...
(Date:10/3/2018)... ... 03, 2018 , ... Fit4D, a leading diabetes management technology-enabled ... Jimmy Lee, as Strategic Advisor to the company’s board. Mr. Lee is a ... a Senior Executive at Anthem, he had P&L accountability for $35 billion of ...
Breaking Biology News(10 mins):
(Date:9/27/2018)... ... September 26, 2018 , ... NDA Partners Chairman ... senior quality, regulatory, and in vitro diagnostic device expert with more than 28 ... joined the firm as an Expert Consultant. Her experience includes leadership roles in ...
(Date:9/27/2018)... BUDAPEST, Hungary and CAMBRIDGE, Mass. (PRWEB) , ... ... ... headquartered in Budapest with US offices in Cambridge, MA, announce today that Holotype ... customers or collaborators at the annual meeting of the American Society for Histocompatibility ...
(Date:9/15/2018)... ... ... Next-generation genomic sequencing is transforming what is known about pediatric cancer and ... the sheer size of genomics data has made sharing across the global scientific community ... advance cures by reducing the technological barriers to data sharing and analysis. Developed by ...
(Date:9/12/2018)... ... September 11, 2018 , ... Sterlitech Corporation, a global leader ... membranes from Fluid Technology Solutions (FTS H2O) to their offering of filtration products. ... cellulose triacetate (CTA) material. The highly hydrophilic nature of the CTA FO membranes ...
Breaking Biology Technology: